

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No.)*

Novus Therapeutics, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

67011N204

(CUSIP Number)

December 22, 2020

(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, *see* the Notes).

1	Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only) Cormorant Global Healthcare Master Fund, LP
2	Check the Appropriate Box if a Member of a Group (See Instructions) (a) <input type="checkbox"/> (b) <input checked="" type="checkbox"/>
3	SEC Use Only
4	Citizenship or Place of Organization. Cayman Islands
	5 Sole Voting Power 0 shares
	6 Shared Voting Power Number of Shares Beneficially Owned by Each Reporting Person With 1,415,500 shares (#) Refer to Item 4 below.
	7 Sole Dispositive Power 0 shares
	8 Shared Dispositive Power 1,415,500 shares (#) Refer to Item 4 below.
9	Aggregate Amount Beneficially Owned by Each Reporting Person 1,415,500 shares (#) Refer to Item 4 below.
10	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) <input type="checkbox"/> N/A
11	Percent of Class Represented by Amount in Row (9)* 9.89% (#) Refer to Item 4 below.
12	Type of Reporting Person (See Instructions) PN (Partnership)
(#) Does not include additional shares of Common Stock issuable upon the conversion of shares of Series X1 Convertible Preferred Stock held by the Reporting Persons, the terms of which limit the extent to which such shares can be converted into shares of Common Stock. See Item 4 below.	

1	Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only)
	Cormorant Global Healthcare GP, LLC
2	Check the Appropriate Box if a Member of a Group (See Instructions) (a) <input type="checkbox"/> (b) <input checked="" type="checkbox"/>
3	SEC Use Only
4	Citizenship or Place of Organization. Delaware
	5 Sole Voting Power
	0 shares
	6 Shared Voting Power
Number of Shares Beneficially Owned by Each Reporting Person With	1,415,500 shares (#)
	Refer to Item 4 below.
	7 Sole Dispositive Power
	0 shares
	8 Shared Dispositive Power
	1,415,500 shares (#)
	Refer to Item 4 below.
9	Aggregate Amount Beneficially Owned by Each Reporting Person 1,415,500 shares (#) Refer to Item 4 below.
10	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) <input type="checkbox"/> N/A
11	Percent of Class Represented by Amount in Row (9)* 9.89% (#) Refer to Item 4 below.
12	Type of Reporting Person (See Instructions) OO (Limited Liability Company)
(#) Does not include additional shares of Common Stock issuable upon the conversion of shares of Series X1 Convertible Preferred Stock held by the Reporting Persons, the terms of which limit the extent to which such shares can be converted into shares of Common Stock. See Item 4 below.	

1	Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only)
	Cormorant Asset Management, LP
2	Check the Appropriate Box if a Member of a Group (See Instructions)
	(a) <input type="checkbox"/>
	(b) <input checked="" type="checkbox"/>
3	SEC Use Only
4	Citizenship or Place of Organization.
	Delaware
	5 Sole Voting Power
	0 shares
	6 Shared Voting Power
Number of Shares Beneficially Owned by Each Reporting Person With	1,415,500 shares (#) Refer to Item 4 below.
	7 Sole Dispositive Power
	0 shares
	8 Shared Dispositive Power
	1,415,500 shares (#) Refer to Item 4 below.
9	Aggregate Amount Beneficially Owned by Each Reporting Person
	1,415,500 shares (#) Refer to Item 4 below.
10	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
	<input type="checkbox"/> N/A
11	Percent of Class Represented by Amount in Row (9)*
	9.89% (#) Refer to Item 4 below.
12	Type of Reporting Person (See Instructions)
	PN (Partnership)
(#) Does not include additional shares of Common Stock issuable upon the conversion of shares of Series X1 Convertible Preferred Stock held by the Reporting Persons, the terms of which limit the extent to which such shares can be converted into shares of Common Stock. See Item 4 below.	

1	Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only)
	Bihua Chen
2	Check the Appropriate Box if a Member of a Group (See Instructions) (a) <input type="checkbox"/> (b) <input checked="" type="checkbox"/>
3	SEC Use Only
4	Citizenship or Place of Organization.
	United States
	5 Sole Voting Power
	0 shares
	6 Shared Voting Power
Number of Shares Beneficially Owned by Each Reporting Person With	1,415,500 shares (#) Refer to Item 4 below.
	7 Sole Dispositive Power
	0 shares
	8 Shared Dispositive Power
	1,415,500 shares (#) Refer to Item 4 below.
9	Aggregate Amount Beneficially Owned by Each Reporting Person
	1,415,500 shares (#) Refer to Item 4 below.
10	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) <input type="checkbox"/> N/A
11	Percent of Class Represented by Amount in Row (9)*
	9.89% (#) Refer to Item 4 below.
12	Type of Reporting Person (See Instructions)
	IN (Individual)
(#) Does not include additional shares of Common Stock issuable upon the conversion of shares of Series X1 Convertible Preferred Stock held by the Reporting Persons, the terms of which limit the extent to which such shares can be converted into shares of Common Stock. See Item 4 below.	

Item 1.

- (a) Name of Issuer
Novus Therapeutics, Inc.
- (b) Address of Issuer's Principal Executive Offices
1990 MacArthur Blvd., Suite 550 Irvine, CA 92612

Item 2.

- (a) Name of Person Filing
Cormorant Global Healthcare Master Fund, LP
Cormorant Global Healthcare GP, LLC
Cormorant Asset Management, LP
Bihua Chen
- (b) Address of Principal Business Office or, if none, Residence
200 Clarendon Street, 52nd Floor
Boston, MA 02116
- (c) Citizenship
Cormorant Global Healthcare Master Fund, LP - Cayman Islands
Cormorant Global Healthcare GP, LLC - Delaware
Cormorant Asset Management, LP - Delaware
Bihua Chen - United States
- (d) Title of Class of Securities
Common Stock
- (e) CUSIP Number
67011N204
-

Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

(a)

- Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
- (b) Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
- (c) Insurance Company as defined in Section 3(a)(19) of the Act
- (d) Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
- (e) An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
- (f) An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
- (g) A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
- (h) A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
- (i) A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
- (j) A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
- (k) Group, in accordance with §240.13d-1(b)(1)(ii)(K).

Item 4. Ownership***

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

(a) Amount Beneficially Owned***

Cormorant Global Healthcare Master Fund, LP – 1,415,500 shares (#)
Cormorant Global Healthcare GP, LLC – 1,415,500 shares (#)
Cormorant Asset Management, LP – 1,415,500 shares (#)
Bihua Chen – 1,415,500 shares (#)

(b) Percent of Class

Cormorant Global Healthcare Master Fund, LP – 9.89% (#)
Cormorant Global Healthcare GP, LLC – 9.89% (#)
Cormorant Asset Management, LP – 9.89% (#)
Bihua Chen – 9.89% (#)

(c) Number of shares as to which such person has:

(i) sole power to vote or to direct the vote

Cormorant Global Healthcare Master Fund, LP - 0 shares
Cormorant Global Healthcare GP, LLC - 0 shares
Cormorant Asset Management, LP - 0 shares
Bihua Chen - 0 shares

(ii) shared power to vote or to direct the vote

Cormorant Global Healthcare Master Fund, LP – 1,415,500 shares (#)
Cormorant Global Healthcare GP, LLC – 1,415,500 shares (#)
Cormorant Asset Management, LP – 1,415,500 shares (#)
Bihua Chen – 1,415,500 shares (#)

(iii) sole power to dispose or to direct the disposition of

Cormorant Global Healthcare Master Fund, LP - 0 shares
Cormorant Global Healthcare GP, LLC - 0 shares
Cormorant Asset Management, LP - 0 shares
Bihua Chen - 0 shares

(iv) shared power to dispose or to direct the disposition of

Cormorant Global Healthcare Master Fund, LP – 1,415,500 shares (#)
Cormorant Global Healthcare GP, LLC – 1,415,500 shares (#)
Cormorant Asset Management, LP – 1,415,500 shares (#)
Bihua Chen – 1,415,500 shares (#)

*** Shares reported herein for Cormorant Asset Management, LP represent shares which are beneficially by Cormorant Global Healthcare Master Fund, LP (the “Master Fund”) as reported herein. Cormorant Global Healthcare GP, LLC serves as the general partner of the Master Fund. Cormorant Asset Management, LP serves as the investment manager to the Master Fund. Bihua Chen serves as the managing member of Cormorant Global Healthcare GP, LLC and the general partner of Cormorant Asset Management, LP. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or his pecuniary interest therein.

(#) Does not include additional shares of common stock of the Issuer (“Common Stock”) issuable upon the conversion of shares of Series X1 Preferred stock of the Issuer (“Preferred Stock”) owned by the Master Fund. Under its terms, the Preferred Stock may be converted to Common Stock only to the extent that such conversion would not cause the holder thereof, together with its affiliates and any other person or entity acting as a group, to beneficially own in excess of 9.9% (subject to adjustment in accordance with the terms of the Preferred Stock) of the shares of Common Stock then outstanding. If not for such limitation on conversion, the Reporting Persons would beneficially own in excess of 9.9% of the Issuer’s outstanding shares of Common Stock.

Item 5. Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [].

Item 6. Ownership of More than Five Percent on Behalf of Another Person

Not applicable.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

Not applicable.

Item 8. Identification and Classification of Members of the Group

Not applicable.

Item 9. Notice of Dissolution of Group

Not applicable.

Item 10. Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

Exhibits Exhibit

99.1 Joint Filing Agreement by and among the Reporting Persons.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this Statement is true, complete and correct.

January 4, 2020

CORMORANT GLOBAL HEALTHCARE MASTER FUND, LP
By: Cormorant Global Healthcare GP, LLC
its General Partner

By: /s/ Bihua Chen
Bihua Chen, Managing Member

CORMORANT GLOBAL HEALTHCARE GP, LLC

By: /s/ Bihua Chen
Bihua Chen, Managing Member

CORMORANT ASSET MANAGEMENT, LP
By: Cormorant Asset Management GP, LLC
its General Partner

By: /s/ Bihua Chen
Bihua Chen, Managing Member

/s/ Bihua Chen
Bihua Chen

JOINT FILING AGREEMENT

This Joint Filing Agreement, dated as of January 4, 2020, is by and among Cormorant Global Healthcare Master Fund, LP, Cormorant Global Healthcare GP, LLC, Cormorant Asset Management, LP and Bihua Chen (collectively, the “Filers”).

Each of the Filers may be required to file with the United States Securities and Exchange Commission a statement on Schedule 13D and/or 13G with respect to shares of Common Stock of Novus Therapeutics, Inc. beneficially owned by them from time to time.

Pursuant to and in accordance with Rule 13(d)(1)(k) promulgated under the Securities Exchange Act of 1934, as amended, the Filers hereby agree to file a single statement on Schedule 13D and/or 13G (and any amendments thereto) on behalf of each of the Filers, and hereby further agree to file this Joint Filing Agreement as an exhibit to such statement, as required by such rule.

This Joint Filing Agreement may be terminated by any of the Filers upon written notice or such lesser period of notice as the Filers may mutually agree.

Executed and delivered as of the date first above written.

CORMORANT GLOBAL HEALTHCARE MASTER FUND, LP
By: Cormorant Global Healthcare GP, LLC
its General Partner

By: /s/ Bihua Chen
Bihua Chen, Managing Member

CORMORANT GLOBAL HEALTHCARE GP, LLC

By: /s/ Bihua Chen
Bihua Chen, Managing Member

CORMORANT ASSET MANAGEMENT, LP
By: Cormorant Asset Management GP, LLC
its General Partner

By: /s/ Bihua Chen
Bihua Chen, Managing Member

/s/ Bihua Chen
Bihua Chen